Breaking news on the treatment front!


We Nerdy Girls are abuzz about the a-mazing clinical trial data reported out by Merck on its investigational antiviral pill. Here’s what we know so far:

➡️ Merck’s antiviral pill reduced by 50% the chances that newly diagnosed COVID-19 patients would be hospitalized over a 1-month period relative to placebo

➡️ No red flags raised re: safety profile of the drug in the study population

➡️ Trial was stopped early – in consultation with an independent data monitoring committee – due to outsized effect sizes among early study participants (~775 adults of the originally planned 1,500). Often this happens when it’s no longer considered ethically appropriate to withhold a treatment from study participants and/or delay an effective drug from market approval.

The case isn’t quite closed, however. More scrutiny of safety data is needed – especially considering that the drug relies on a novel mechanism (cite below). AP reports that FDA review may come within weeks, so a rigorous scrutiny of the data isn’t far away.

Happily, other companies’ antiviral efforts also appear promising (cite below), providing some reassurance that this trial isn’t a fluke.

This could be a game-changer. We will stay on the reporting trail.

Your Nerdy Girls


Press release from Merck

Stat News article describing novel mechanism

AP report

Other companies with promising candidates

Link to Original FB Post